25 C
Vientiane
Friday, May 30, 2025
spot_img
Home Blog Page 2368

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE – Media OutReach – 6 June 2022 Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that PADCEV (enfortumab vedotin) has been approved by the Health Sciences Authority of Singapore as monotherapy for the treatment of adult patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

The Singapore approval follows the earlier European Commission (EC) approval of PADCEV on 13 April 2022. Singapore is among the first two countries in Asia Pacific (alongside Japan) to receive market authorisation. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.

“This is a significant milestone for Singapore. The approval of enfortumab vedotin provides new treatment options for patients living with advanced urothelial cancer and have had limited treatment options and low survival rates. We look forward to working with other health authorities across the region to ensure more patients living with advanced urothelial cancer can access this new treatment option as soon as possible,” said Verma, Vivek, Head of Medical Affairs International Markets & Greater China, Astellas.

The EV-301 trial[1] compared enfortumab vedotin to chemotherapy in adult patients (n=608) with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. At the time of the pre-specified interim analysis, patients who received enfortumab vedotin (n=301) in the trial lived a median of 3.9 months longer than those who received chemotherapy (n=307). Median OS was 12.9 vs. 9 months, respectively [Hazard Ratio=0.70 (95% Confidence Interval [CI]: 0.56, 0.89), p=0.001]. Across clinical trials, the most common adverse reactions with enfortumab vedotin were alopecia, fatigue, decreased appetite, peripheral sensory neuropathy, diarrhea, nausea, pruritus, dysgeusia, anemia, weight decreased, rash maculo-papular, dry skin, vomiting, aspartate aminotransferase increased, hyperglycemia, dry eye, alanine aminotransferase increased and rash.

Urothelial cancer is the most common type of bladder cancer, accounting for 90 per cent of all bladder cancer cases[2]. In the Asia Pacific region, an estimated 130,000 people were diagnosed with urothelial cancer in 2021, and more than 65,000 have died as a result of the disease[3]. Urothelial cancer is also found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra[4].

PADCEV has received marketing authorization in the United States, Japan, Canada, the European Union (EU), Israel, The United Kingdom, Switzerland, Brazil and Singapore.


[1] Results from the EV-301 trial are intended to support global registrations for enfortumab vedotin.

[2] American Society of Clinical Oncology. Bladder cancer: introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed March 16, 2022.

[3] Cancer Today. Bladder Cancer Factsheet 2020. https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf. Accessed March 16, 2022.

[4] American Society of Clinical Oncology. Bladder cancer: introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed March 16, 2022.

About PADCEV™ (enfortumab vedotin)

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer[5]. Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis) [5] PADCEV is co-developed by Astellas and Seagen.

About the EV-301 Trial
The EV-301 trial () was a global, multicenter, open-label, randomized phase 3 trial designed to evaluate enfortumab vedotin versus physician’s choice of chemotherapy (docetaxel, paclitaxel or vinflunine) in 608 patients with locally advanced or metastatic urothelial ca Singapore Health Sciences Authority ncer who were previously treated with a PD-1/L1 inhibitor and platinum-based therapies[6]. The primary endpoint was overall survival and secondary endpoints included progression-free survival, overall response rate, duration of response and disease control rate, as well as assessment of safety/tolerability and quality-of-life parameters. Results were published in the

About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at .

About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.

Important Safety Information
The Singapore approved package insert can be accessed at the Singapore Health Sciences Authority . Report any adverse events to Astellas Pharma Singapore Pte. Ltd. at pv@sg.astellas.com. Alternatively, adverse events may be reported to the Health Sciences Authority at Tel: 6866 1111, Fax: 6478 9069 or online at .

About the Astellas and Seagen Collaboration
Astellas and Seagen are co-developing enfortumab vedotin under a 50:50 worldwide development and commercialization collaboration. In the United States, Astellas and Seagen co-promote enfortumab vedotin. In the Americas outside the US, Seagen holds responsibility for commercialization activities and regulatory filings. Outside of the Americas, Astellas holds responsibility for commercialization activities and regulatory filings.

Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Seagen Forward-Looking Statements
Certain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of PADCEV, including its efficacy, safety and therapeutic uses, and the potential to make PADCEV available to patients in Europe. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibilities that we may experience delays or setbacks in seeking pricing and reimbursement approvals or otherwise in commercializing PADCEV in Europe; that adverse events or safety signals may occur; and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


[5] Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13. / PADCEV [package insert]. Northbrook, Ill.: Astellas Pharma US, Inc.

[6] Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 10.1056/NEJMoa2035807.

Cyber-Attacks on Industrial Assets Cost Firms Millions

Trend Micro study reveals the impact of threats to ICS/OT environments

HONG KONG SAR – Media OutReach – 6 June 2022 – Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybersecurity leader, today announced new research* revealing that 89% of electricity, oil & gas, and manufacturing firms have experienced cyber-attacks impacting production and energy supply over the past 12 months.

To read a full copy of the research, The State of Industrial Cybersecurity, please visit: https://resources.trendmicro.com/IoT-survey-report.html

“Across the globe, industrial locations are going digital to drive sustainable growth. But this has invited a deluge of threats which they are ill-equipped to mitigate, causing major financial and reputational damage,” said William Malik, vice president of infrastructure of strategies at Trend Micro. “Managing these heavily networked IT and OT environments effectively requires an experienced partner with the foresight and breadth of capabilities needed to deliver best-in-class protection across both environments.”

The findings come a year after the Colonial Pipeline ransomware attack, which forced OT systems at the provider offline for several days, leading to major fuel shortages up and down the US East Coast. It is still the largest critical infrastructure (CNI) attack of its kind.

Around half of the industrial sector organizations affected by CNI attacks made efforts to improve cybersecurity infrastructures but do not always have sufficient resources or knowledge in place to defend against future threats.

Of the responding organizations that suffered cyber disruption to their operational technology and industrial control systems (OT/ICS), the average financial damages amount to approximately $2.8 million, with the oil & gas industry suffering the most.

Almost three-quarters (72%) of respondents admitted they experienced cyber disruption to their ICS/OT environments at least six times during the year.

The research also found that:

  • 40% of respondents could not block the initial attack
  • 48% of those who say there have been some disruptions do not always make improvements to minimize future cyber risks.
  • Future investments in cloud systems (28%) and private 5G deployments (26%) were the top two drivers of cybersecurity among respondents.
  • The OT security function tends to be less mature than IT on average in terms of risk-based security.

The addition of cloud, edge, and 5G in the mixed IT and OT environments has rapidly transformed industrial operations and systems. Organizations must stay ahead of the curve and take security measures to protect business assets. Improving risk and threat visibility is a curtail first step to a secure industrial cloud and private network.

“Trend Micro exceeded our expectations right from the start, and we haven’t looked back since,” said David Levine, vice president of Information Security and CISO, Ricoh USA. “With Trend Micro, you get an immediate reaction, escalation, and communication. It’s about effective, innovative tools, coupled with a great partnership.”

Trend Micro’s unified cybersecurity platform provides streamlined detection and response, adaptive to ICS and 5G, to equip organizations in the complex industrial environment where different technologies and applications are integrated to support business operations. To learn more about Trend Micro ICS/OT security, please visit: http://www.trendmicro.com/en_hk/business/solutions/iot/ics-ot.html

*Trend Micro polled 900 ICS cybersecurity leads in Germany, the US, and Japan’s manufacturing, oil & gas, and electricity sectors to compile its new study.

About Trend Micro

Trend Micro, a global cybersecurity leader, helps make the world safe for exchanging digital information. Fueled by decades of security expertise, global threat research, and continuous innovation, Trend Micro’s cybersecurity platform protects hundreds of thousands of organizations and millions of individuals across clouds, networks, devices, and endpoints. As a leader in cloud and enterprise cybersecurity, the platform delivers a powerful range of advanced threat defense techniques optimized for environments like AWS, Microsoft, and Google, and central visibility for better, faster detection and response. With 7,000 employees across 65 countries, Trend Micro enables organizations to simplify and secure their connected world.

#TrendMicro

The Beauty of Recycling: Watsons Launches Regionwide Recycling Programme with L’Oréal

HONG KONG SAR – Media OutReach – 6 June 2022 – In celebration of World Environment Day, A.S. Watson Group’s flagship health and beauty brand Watsons is extending its regionwide recycling programme to Hong Kong. This rides on the hugely successful launch of recycling programmes in Taiwan, Thailand, and Indonesia.

as.jpg

Malina Ngai (right), CEO of A.S. Watson (Asia and Europe) is excited to extend Watsons’ regionwide recycling programme to Hong Kong with Eva Yu (left), President & Managing Director of L’Oréal Hong Kong

Watsons understands that its responsibility towards the environment goes beyond the product range. Inspiring behavioural change amongst its customers is of utmost importance to help create a more sustainable world. As such, Watsons has rolled out a regionwide recycling programme with L’Oréal.

In Taiwan, Watsons has worked with Maybelline to set up recycling bins in stores. For every empty bottle that is recycled, Maybelline will make donation to Re-Think to run sustainability education programmes. Meanwhile in Thailand, Watsons’ customers can recycle their PET plastic bottles at the Garnier Refund Machine in selected stores and earn a free Garnier Pink Micellar Water; while in Indonesia, Watsons has launched a recycling programme with Garnier to encourage customers to recycle plastic bottles at Watsons stores.

To further widen its sustainability impact, the regionwide recycling programme has now been extended to the fourth market, Hong Kong. To accelerate its sustainability endeavors, Watsons Hong Kong has partnered with L’Oréal to roll out the ‘Beauty for the Future’ recycling campaign. From now on, customers can recycle the cleaned containers of any beauty brand, including foundation bottles, mascara wands, skincare tubs, and lipstick tubes at around 170 Watsons stores across the city in exchange for rewards in the city’s largest loyalty platform MoneyBack.

Once collected, V Cycle will break down the wastes, separate them by materials, and work with local partners to transform them into new raw materials. The scaled-up campaign goal is to collect 250,000 containers in the 12 months following the official launch, which is equivalent to the height of two Mount Everests when stacked up[1].

“Pre-loved beauty packages have their place, but that place is not in landfills. Our goal is to meet it head-on with the first cross-brand recycling programme involving 18 of our beauty brands in 2021. Today, we are thrilled to work with partners along the value chain to expand the programme and positively impact people’s lives while preserving the planet,” said Eva Yu, President & Managing Director of L’Oréal Hong Kong. “With the scaled-up recycling campaign as part of our ‘L’Oréal for the Future’ sustainability programme, we want to further inspire and influence how our consumers think and what they do about packaging wastes – not as something to toss out, but as a resource that can be recycled and used again, and sustainably, reducing the impact on our environment. Our partnership with Watsons and V Cycle will help make this a reality.”

“At Watsons, we believe Going Green is The New Beautiful. We made it our purpose to do the right things for our customers and the planet. Sharing a common sustainability vision with L’Oréal, we appreciate this Beauty of Recycling partnership in the region to educate customers as well as engage them in action so that together we can create a bigger impact to the planet today and tomorrow,” said Malina Ngai, CEO of A.S. Watson (Asia and Europe).


[1] Taking a median value of 7cm per container, the aggregate height is 17,500 meters when stacked up.

About Watsons

Watsons is the leading O+O (Offline plus Online) health and beauty retailer in Asia, currently operating over 8,000 stores and more than 1,500 pharmacies in 16 Asian and European markets. Watsons continually sets the standards in the health, wellness and beauty market, providing personalised advice and counselling in health, beauty and personal care on top of its market-leading product range, making customers LOOK GOOD, DO GOOD, FEEL GREAT every day. Since 2009, Watsons has been the No.1 pharmacy/ drugstore brand in Asia*. Watsons is the flagship health and beauty brand of A.S. Watson Group.

*Campaign Asia-Pacific “Asia’s Top 1,000 Brands” survey of over 8,000 respondents across 14 markets in Asia Pacific Region

About A.S. Watson Group
Established in 1841, A.S. Watson Group is the world’s largest international health and beauty retailer operating over 16,400 stores under 12 retail brands in 29 markets, with about 130,000 employees worldwide. For the fiscal year 2021, A.S. Watson Group recorded revenue of US$22 billion. Every year, we are serving over 5.5 billion shoppers via our O+O (Offline plus Online) platforms, providing tech-enabled retail experience to customers offline and online.

A.S. Watson Group is also a member of the world-renowned multinational conglomerate CK Hutchison Holdings Limited, which has four core businesses ‐ ports and related services, retail, infrastructure and telecommunications in over 50 countries.

A.S. Watson Group has launched a Greener Stores Global Framework to accelerate the transformation of retail towards lower-environmental impact stores to achieve a reduction in carbon emissions, water usage and landfill waste as well as leverage its scale for good to speed up the global movement towards a more sustainable future. The A.S. Watson Greener Stores Global Framework aims to forge and inspire its businesses to build a stronger sustainability culture and practice in the way it designs, constructs, operates and maintains its stores.

Please visit www.aswatson.com/our-company/o-and-o-strategy/ for more information.

#ASWatsonGroup

Police Seize Over 10,000,000 Amphetamine Pills in Bokeo Province 

Police officials arrest two men with amphetamine pills.

Bokeo authorities seized over 10,000,000 amphetamine pills from two suspects on Friday.

Vientiane-Vang Vieng Expressway Resumes Operation After Shooting 

Tunnels in Hin Heup district.

The Vientiane-Vang Vieng expressway continues to operate and ensure customer safety following a shooting at the exit tunnel between Hin Heup and Vientiane.

Spackman Media Group Artist Son Suk-ku Ranks #1 In The Brand Reputation Of Actors In Korea

  • Spackman Media Group artist Son Suk-ku took the top spot in the brand reputation of actors in Korea, based on the Korea Corporate Reputation Research Institute
  • Son Suk-ku’s latest film THE ROUNDUP exceeded the 9 million viewer mark, topping the weekend box office for three consecutive weeks since its release
  • Following his role in THE ROUNDUP, Son Suk-ku is set to star in two highly anticipated Netflix original K-dramas, D.P. Season 2 and MURDEROUS TOY

SINGAPORE – Media OutReach – 6 June 2022 Spackman Entertainment Group Limited (the “Group“), one of Korea’s leading entertainment production groups founded in 2011 by media & technology investor Charles Spackman, wishes to announce that Son Suk-ku of the Group’s associated company, Spackman Media Group Limited (“Spackman Media Group“), took the top spot in the brand reputation of actors in Korea, according to the Korea Corporate Reputation Research Institute.

The result was obtained by the brand analysis of 50 actors from May 5 to June 5. It studied big data from consumers’ brand reception and the volume of media & community interest on the actors. Son Suk-ku scored 84.57% in the brand reputation ratings, ranking first among the 50 actors.

Son Suk-ku’s latest film, THE ROUNDUP, a sequel to the 2017 hit THE OUTLAWS, surpassed the 9 million viewer mark. The crime thriller film topped the weekend box office for three weeks in a row since the day of its release on May 18. The film was pre-sold to 132 countries around the world, including Singapore, China, Thailand, Vietnam, Indonesia and France, as well as the regions of North America and Eastern Europe.

Following his role in THE ROUNDUP, Son Suk-ku of Spackman Media Group is set to headline in two upcoming highly anticipated Netflix original K-dramas, D.P. Season 2 and MURDEROUS TOY. Alongside Son Suk-ku, D.P. Season 2 brings back main cast members Jung Hae-in, Koo Gwan-hwa, Kim Seong-gyun, while adding newcomers Ji Jin-hee, and Kim Ji-hyun. Based on the webtoon D.P DOG DAY by Kim Bo-tong, D.P. tells the story of a team of Korean military police with their mission to catch deserters. The series is directed by Han Jun-hee and co-written by Kim Bo-tong.

Produced by Showbox, MURDEROUS TOY stars Son Suk-ku of Spackman Media Group and Choi Woo-shik of the film PARASITE (2019). The Netflix K-drama is based on the popular webtoon series of the same name and is scheduled for release in the second half of this year.

Son Suk-ku is represented by SBD Entertainment Inc. (“SBD Entertainment“), a wholly-owned subsidiary of Spackman Media Group that represents and manages the careers of 12 artists. In addition to Son Suk-ku, SBD Entertainment also represents one of Korea’s rapidly rising young actors, Han Ji-hyun of popular K-drama THE PENTHOUSE 3, who won the Best Rookie Female Actor in the 2021 Brand Customer Loyalty Awards in Korea and endorsed luxury brand Gucci in April 2021.

About Spackman Entertainment Group Limited

Spackman Entertainment Group Limited (“SEGL” or the “Company“), and together with its subsidiaries, (the “Group“), is one of Korea’s leading entertainment production groups. SEGL is primarily engaged in the independent development, production, presentation, and financing of theatrical motion pictures in Korea.

The Company was founded in 2011 by renowned media and technology investor Charles Spackman who served as the Company’s Executive Chairman until 2017. For the past two decades, Mr. Charles Spackman has been a powerhouse in the Korean entertainment industry starting in the early 2000’s with the pioneering success of Sidus Pictures, the largest movie production company at the time and the first to be listed in Korea. Mr. Spackman is also the Founder, Chairman and Chief Executive Officer of the global investment firm, Spackman Group. For more information, please visit and .

Since its founding, SEGL had produced more than 30 major motion pictures including a number of the highest grossing and award-winning films in Korea, namely #ALIVE (2020), CRAZY ROMANCE (2019), DEFAULT (2018), MASTER (2016), THE PRIESTS (2015), SNOWPIERCER (2013), COLD EYES (2013) and ALL ABOUT MY WIFE (2012).

Our films are theatrically distributed and released in Korea and overseas markets, as well as for subsequent post-theatrical worldwide release in other forms of media, including online streaming, cable TV, broadcast TV, IPTV, video-on-demand, and home video/DVD, etc. Generally, we release our motion pictures into wide-theatrical exhibition initially in Korea, and then in overseas and ancillary markets.

The Group also invests into and produces Korean television dramas. In addition to our content business, we also own equity stakes in entertainment-related companies and film funds that can financially and strategically complement our existing core operations. SEGL is listed on the Catalist of the Singapore Exchange Securities Trading Limited under the ticker 40E.

Production Labels

SEGL owns Novus Mediacorp Co., Ltd. (“Novus Mediacorp“), an investor, presenter, and/or post-theatrical distributor for a total of 79 films (58 Korean and 21 foreign) including ROSE OF BETRAYAL, THE OUTLAWS and SECRETLY, GREATLY, which was one of the biggest box office hits of 2013 starring Kim Soo-hyun of MY LOVE FROM THE STARS, as well as FRIEND 2: THE GREAT LEGACY. In 2012, Novus Mediacorp was also the post-theatrical rights distributor of ALL ABOUT MY WIFE, a top-grossing romantic comedy produced by Zip Cinema. In 2018, THE OUTLAWS, co-presented by Novus Mediacorp broke the all-time highest Video On Demand (“VOD“) sales records in Korea. For more information, please visit

The Company owns a 100% equity interest in Simplex Films Limited (“Simplex Films“) which is an early stage film production firm. The maiden film of Simplex Films, JESTERS: THE GAME CHANGERS (2019), was released in Korea on 21 August 2019. Simplex Films has several line-up of films including HURRICANE BROTHERS (working title).

The Company owns a 100% equity interest in Take Pictures Pte. Ltd. (“Take Pictures“) which produced STONE SKIPPING (2020) and THE BOX (2021), and shall release THE GUEST in the second half of 2022 and A MAN OF REASON, with the previous working title GUARDIAN in 2022 tentatively.

The Company owns a 100% equity interest in Greenlight Content Limited (“Greenlight Content“) which is mainly involved in the business of investing into dramas and movies, as well as providing consulting services for the production of Korean content. Through the acquisition of Greenlight Content, the Group’s first co-produced drama, MY SECRET TERRIUS, starring top Korean star, So Ji Sub, achieved #1 in drama viewership ratings for its time slot and recorded double digits for its highest viewership ratings. Greenlight Content was one of the main investors of MY SECRET TERRIUS.

The Company owns a 20% equity interest in The Makers Studio Co. Ltd., which plans to produce and release four upcoming films, the first of which will be THE ISLAND OF THE GHOST’S WAIL, a comedy horror film.

Talent Representation

The Company holds an effective shareholding interest of 43.88% in Spackman Media Group Limited (“SMGL“). SMGL, a company incorporated in Hong Kong, together with its subsidiaries, is collectively one of the largest entertainment talent agencies in Korea in terms of the number of artists under management, including some of the top names in the Korean entertainment industry. SMGL operates its talent management business through renowned agencies such as MSteam Entertainment Co., Ltd. (Son Ye-jin, Wi Ha-jun, Lee Min-jung, Ko Sung-hee), SBD Entertainment Inc. (Son Suk-ku, Han Ji-hyun, Lee Cho-hee, Park Keun-rok), UAA&CO Inc. (Kim Sang-kyung, Kim Hye-ri, Kim Ji-young, Wang Ji-won), Play Content Co., Ltd. (Kang Min-ji, Hwang-hwi) and Kook Entertainment Co., Ltd. (Baek Si-won, Shin Ji-woong). Through these full-service talent agencies in Korea, SMGL represents and guides the professional careers of a leading roster of award-winning actors/actresses in the practice areas of motion pictures, television, commercial endorsements, and branded entertainment. SMGL leverages its unparalleled portfolio of artists as a platform to develop, produce, finance and own the highest quality of entertainment content projects, including theatrical motion pictures, variety shows and TV dramas. This platform also creates and derives opportunities for SMGL to make strategic investments in development stage businesses that can collaborate with SMGL artists. SMGL is an associated company of the Company. For more information, please visit

The Company owns a 100% equity interest in Constellation Agency Pte. Ltd. (“Constellation Agency“). Constellation Agency, which owns The P Factory Co., Ltd. (“The P Factory“) and Platform Media Group Co., Ltd. (“PMG“), is primarily involved in the business of overseas agency for Korean artists venturing into the overseas market. The P Factory is an innovative marketing solutions provider specializing in event and branded content production. PMG is a talent management agency which represents and manages the careers of major artists in film, television, commercial endorsements and branded entertainment.

Strategic Businesses

The Company also operates a café-restaurant, Upper West, in the Gangnam district of Seoul and own a professional photography studio, noon pictures Co., Ltd.

For more details, please visit

#SpackmanEntertainmentGroup

Epicor Delivers People-Centric, Open, and Connected Updates Across Latest Release of Epicor Industry ERP Cloud Portfolio

HONG KONG SAR – Media OutReach – 6 June 2022 – Epicor, a global leader of industry-specific enterprise software designed to promote business growth, today introduced a variety of new features across the latest release of the Epicor Industry ERP Cloud portfolio, including updates for Epicor Kinetic for manufacturing, Epicor Prophet 21 for distribution, and Epicor BisTrack for building supply.

The new updates seek to deliver on the company’s continued commitment to build people-centric, open, and connected industry productivity solutions that help the essential businesses that make, move, and sell the things everyone needs succeed in today’s complex market.

“We are on a journey with our customers to help them take advantage of the agility, integration, and security that cloud delivers,” said Steve Murphy, Epicor CEO. “The new capabilities across our latest release of the Epicor Industry ERP Cloud portfolio empower our customers with the deep, industry-specific capabilities, integrations, and business process automations they require to grow their businesses and boost profitability.”

As companies contend with an array of challenges including operational efficiency, supply chain disruption, workforce complexities, and changing customer expectations for digital connectedness, the need for flexible, insights-driven industry productivity solutions has never been greater. In fact, according to the latest Epicor Industry Insights Report 2021, 94 percent of business leaders surveyed stated the cloud is critical to future-proofing their business, and 82 percent said Covid-19 had accelerated their cloud migration plans.

The latest updates across the Epicor Industry ERP Cloud portfolio are built to deliver a variety of integration, automation, and performance capabilities that help customers stay ahead of these challenges and maximize the power of their data.

This includes the introduction of Epicor Automation Studio, a low code integration and synchronization tool embedded natively in Epicor Kinetic and Epicor Prophet 21 that empowers users to connect their data and automate workflows both within their Epicor solutions as well as with more than 1,000 applications and databases.

Additional Epicor platform updates include:

Epicor Kinetic for Manufacturing

  • Epicor CPQ elevates the selling experience and streamlines production through visual product configuration, dynamic pricing, document generation and more. The recent enhancements provide richer integration points across Epicor CPQ for quoting, sales orders, and jobs allowing businesses to improve operational efficiency.
  • Epicor Commerce Connect is a cloud-based, fully integrated, omnichannel digital commerce system that seamlessly integrates your online store with Epicor Kinetic. The recent enhancements drive ease of use and increase efficiency through broadening language packs, enabling payment on account, and additional support for backorder processing.
  • Epicor Application Studio provides an easier and faster way to configure your Epicor Kinetic environment. The newest features allow you to access tool tips on all components and events, retrieve default search options for tables, and become familiar with the new web-based design surface.
  • Dynamic Documents gives Kinetic users the flexibility to design their own forms and drive business actions within the platform.


Epicor Prophet 21 for Distribution

  • Epicor CPQ integration that allows for a seamless connection between sales and operational data, helping improve demand, planning and production.
  • Smart Inventory Planning & Optimization integration through a set of native web applications, providing a single, easy-to-use, and scalable environment with proven inventory and forecast modeling that optimizes inventory stocking policy and improves forecast accuracy.
  • Epicor Report Studio offers more robust reporting options, advanced filters for complex analysis, and easier access to data sources, enhancing the overall performance and ease of the platform.
  • Epicor Identity Provider (IdP) provides additional security for cloud customers by serving as an identity aggregator. With the recent release, single sign-on with IdP will now be supported for a variety of Epicor applications.


Epicor BisTrack for Building Supply

  • Epicor CPQ integration updates including an improved 3D configurator helping customers see finished product installed in their environment.
  • Geotab fleet management integration to more easily track vehicle location and status.
  • Epicor ECM Accounts Payable automation that helps streamline business document processes and reduce errors through elegant, intuitive designs that are easy to learn and understand.
  • Verifone payment integration for UK customers.

For more information about the Epicor Industry ERP Cloud portfolio and latest updates, please visit our website.

About Epicor

Epicor equips hard-working businesses with enterprise solutions that keep the world turning. For 50 years, Epicor customers in the automotive, building supply, distribution, manufacturing, and retail industries have trusted Epicor to help them do business better. Innovative Epicor solution sets are carefully curated to fit customer needs and built to respond flexibly to their fast-changing reality. With deep industry knowledge and experience, Epicor accelerates its customers’ ambitions, whether to grow and transform, or simply become more productive and effective. Visit for more information.

Epicor and the Epicor logo are trademarks of Epicor Software Corporation, registered in the United States and other countries. Other trademarks referenced are the property of their respective owners. The product and service offerings depicted in this document are produced by Epicor Software Corporation. Results are not guaranteed, and each user’s experience will vary.

#Epicor

Laos National Assembly to Find Solutions to Economic Problems at Upcoming Session

New National Assembly Building

The Third Ordinary Session of the National Assembly (Ninth Legislature) of Laos will be opened on 13 June and will last through 8 July, Secretary of the National Assembly Pingkham Lasasima has told the media.